Thursday, 21 May 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 21 May 2026
News

Second drug carves out new niche

Posted 21 May 2026 PM

Sanofi has become the latest company to carve out a niche in the BTK inhibitor drug class, with the TGA approving Cenrifki for use in non-relapsing secondary progressive multiple sclerosis (nrSPMS).

It marks just days since the TGA approved Novartis’ Rhapsido for the treatment of chronic spontaneous urticaria, also known as hives that have no known cause.

To see the whole article, please login

Popular

Pharma spend on HCPs doubles
Which Drs really distrust pharma?
World's Most Innovative Pharma is...
High-flyer exits corporate world
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home